INM· Health Care› Drug Manufacturers - Specialty & Generic

InMed Pharmaceuticals Inc.

Stage 3 · Topping · week 9

As of Oct 22, 2026, InMed Pharmaceuticals is in Stage 3, the topping phase, now in week 9 (since Aug 25, 2026). It closed at $1.33, 35.7% below its 52-week high and above its 200-day average, which is rising.

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. More about the company

$1.33

-0.88% today

$7.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is INM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S4 23w

S4 21w

S4 43w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 30w → S1 2w → S4 23w → S1 4w → S4 3w → S1 3w → S4 5w → S1 3w → S4 21w → S1 7w → S4 43w → S1 7w → S2 7w → S3 8w current

Total tracked: 166 weeks across 14 stage runs.

INM among Drug Manufacturers - Specialty & Generic49th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…49	INMInMed Pharmaceuticals Inc.	Stage 3 · wk 9	29	−3.6%

vs 52W High

-35.7%

$0.62 lo$2.07 hi

35.7% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 9

1w13w26w

Week 9, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

11.7%

200 DMA: $1.19 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.14x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

→

Short-term trend flat

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-3.6%

-22.2%

+74.5%

YTD

+18.8%

-38.4%

Scan Membership

Breakout Watch

Latest: 2021-03-19

3 appearances in last 60 days. First seen: 2020-03-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 9 · Vol 0.14x

2026-10-21S3

Wk 9 · Vol 0.49x

2026-10-20S3

Wk 8 · Vol 0.60x

2026-10-19S3

Wk 8 · Vol 0.60x

2026-10-16S3

Wk 8 · Vol 0.07x

2026-10-15S3

Wk 8 · Vol 0.26x

2026-10-14S3

Wk 8 · Vol 0.44x

2026-10-13S3

Wk 7 · Vol 0.41x

2026-10-12S3

Wk 7 · Vol 0.39x

2026-10-09S3

Wk 7 · Vol 0.72x

2026-10-08S3

Wk 7 · Vol 0.33x

2026-10-07S3

Wk 7 · Vol 0.19x

Moving averages & range

50 DMA

$1.37

200 DMA

$1.19

52W High

$2.07

52W Low

$0.62

5D Low

$1.32

Resistance levels (recent highs)

20d High

$1.38

60d High

$1.59

120d High

$1.85

250d High

$2.07

Next resistance

+3.8%

to 20d High

ROE

-156.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 6.6

InMed Pharmaceuticals: quick answers

What stage is InMed Pharmaceuticals in?

As of Oct 22, 2026, InMed Pharmaceuticals (INM) is in Stage 3, the topping phase. It entered Stage 3 on Aug 25, 2026 and is in week 9. What the four stages mean

Is InMed Pharmaceuticals in an uptrend?

Its uptrend has stalled. InMed Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 11.7% above its 200-day average, which is rising.

How far is InMed Pharmaceuticals from its 52-week high?

InMed Pharmaceuticals closed at $1.33 on Oct 22, 2026, 35.7% below its 52-week high of $2.07. Its 52-week low is $0.62.

How has InMed Pharmaceuticals performed over the past year?

As of Oct 22, 2026, InMed Pharmaceuticals is down 38.4% over the past year and up 18.8% so far in 2026.

Which sector and industry is InMed Pharmaceuticals in?

InMed Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.